论文部分内容阅读
目的:比较头孢哌酮-舒巴坦与头孢曲松对慢性心力衰竭患者伴肺部感染的临床疗效。方法:选取医院2015年12月—2016年12月期间收治的慢性心力衰竭伴肺部感染患者80例临床资料,将其随机分为观察组与对照组(每组40例);观察组患者给予头孢哌酮-舒巴坦静脉滴注治疗,对照组患者给予头孢曲松静脉滴注治疗,比较两组患者治疗后的总有效率和细菌清除率。结果:观察组患者治疗后的总有效率97.50%高于对照组为87.50%(P<0.05),细菌清除率为97.37%高于对照组为70.00%(P<0.05)。结论:头孢哌酮-舒巴坦对慢性心力衰竭伴肺部感染患者的临床疗效优于头孢曲松,能有效地清除体内病原菌。
Objective: To compare the clinical efficacy of cefoperazone-sulbactam and ceftriaxone in patients with chronic heart failure and pulmonary infection. Methods: The clinical data of 80 patients with chronic heart failure and pulmonary infection admitted from December 2015 to December 2016 in our hospital were selected and randomly divided into observation group and control group (40 cases in each group). Patients in observation group were given Cefoperazone - sulbactam intravenous infusion of patients in the control group were given intravenous ceftriaxone treatment, the total effective rate and bacterial clearance rate after treatment in both groups were compared. Results: The total effective rate in the observation group was 97.50% higher than that in the control group (87.50%, P <0.05). The bacterial clearance rate was 97.37% in the observation group and 70.00% in the control group (P <0.05). Conclusion: Cefoperazone - sulbactam is superior to ceftriaxone in the treatment of patients with chronic heart failure and pulmonary infection, which can effectively remove pathogenic bacteria in the body.